Replimune Group (NASDAQ:REPL) Issues Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) released its earnings results on Tuesday. The company reported ($0.77) earnings per share for the quarter, FiscalAI reports.

Replimune Group Stock Down 0.9%

REPL opened at $6.97 on Tuesday. The firm has a market capitalization of $546.73 million, a P/E ratio of -2.01 and a beta of 0.73. Replimune Group has a one year low of $2.68 and a one year high of $14.80. The company has a fifty day moving average price of $8.98 and a 200-day moving average price of $7.25. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31.

Insiders Place Their Bets

In other news, Director Kapil Dhingra sold 3,169 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $10.40, for a total transaction of $32,957.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Sarchi sold 5,208 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the transaction, the insider owned 123,088 shares in the company, valued at approximately $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,625 shares of company stock worth $257,607 over the last three months. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds have recently bought and sold shares of the company. CWM LLC grew its position in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Replimune Group in the 2nd quarter valued at $69,000. Russell Investments Group Ltd. grew its holdings in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Replimune Group by 2,020.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after purchasing an additional 9,235 shares during the period. Institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

REPL has been the topic of several research reports. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $3.00 to $13.00 in a research note on Monday, October 20th. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price for the company in a research report on Monday, October 20th. Finally, Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $4.00 to $18.00 in a research report on Monday, October 20th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Hold” and a consensus target price of $9.75.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.